Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 2 × HDAC-42 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Neurofibromatosis 2 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Congenital Abnormalities 1 Carcinoma, Renal Cell 1

Interventions

Bevacizumab 5 Everolimus 4 Sirolimus 2 Lapatinib 2 temsirolimus 1 neratinib 1 icotinib 1 emvododstat 1 brolucizumab 1 brigatinib 1 aflibercept 1 Vascular Endothelial Growth Factor A 1 Valproic Acid 1 Sunitinib 1 Magnetic Resonance Imaging 1 Immunoglobulin G 1 HDAC-42 1 Exome 1 Endostatins 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Axitinib 1 Aspirin 1 AZD 6244 1 89Zr-bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡